The company uses a platform approach to improve small molecule drugs by adding a second small molecule to an existing drug, resulting in enhanced efficacy and lower toxicity. Amplyx's focus is on developing antifungal agents to treat invasive fungal infections, with both intravenous and oral formulations to address the need for treatment in both the hospital and post-discharge settings. Their mission is to save lives by developing a new class of antifungal medicine that overcomes the severe limitations of current therapeutic options, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx's leadership has extensive experience developing drugs to treat infectious diseases and rare conditions.